147 related articles for article (PubMed ID: 24937470)
1. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure.
Shi M; Shtraizent N; Polotskaia A; Bargonetti J; Matsui H
PLoS One; 2014; 9(6):e99351. PubMed ID: 24937470
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
3. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
5. Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β.
Takahashi RU; Takeshita F; Honma K; Ono M; Kato K; Ochiya T
Sci Rep; 2013; 3():2474. PubMed ID: 23959174
[TBL] [Abstract][Full Text] [Related]
6. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
[TBL] [Abstract][Full Text] [Related]
7. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
8. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
[TBL] [Abstract][Full Text] [Related]
10. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
Loo LWM; Gao C; Shvetsov YB; Okoro DR; Hernandez BY; Bargonetti J
Breast Cancer Res Treat; 2019 Feb; 174(1):257-269. PubMed ID: 30470976
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.
Escoll M; Gargini R; Cuadrado A; Anton IM; Wandosell F
Oncogene; 2017 Jun; 36(25):3515-3527. PubMed ID: 28166194
[TBL] [Abstract][Full Text] [Related]
12. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.
Kollareddy M; Dimitrova E; Vallabhaneni KC; Chan A; Le T; Chauhan KM; Carrero ZI; Ramakrishnan G; Watabe K; Haupt Y; Haupt S; Pochampally R; Boss GR; Romero DG; Radu CG; Martinez LA
Nat Commun; 2015 Jun; 6():7389. PubMed ID: 26067754
[TBL] [Abstract][Full Text] [Related]
13. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
[TBL] [Abstract][Full Text] [Related]
14. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
15. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
[TBL] [Abstract][Full Text] [Related]
16. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246.
Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
Br J Cancer; 2022 Nov; 127(11):2060-2071. PubMed ID: 36138076
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
19. [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].
Yang H; Li J; Guo J; Zhang S
Zhongguo Fei Ai Za Zhi; 2012 Apr; 15(4):202-7. PubMed ID: 22510504
[TBL] [Abstract][Full Text] [Related]
20. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
Ellison V; Polotskaia A; Xiao G; Leybengrub P; Qiu W; Lee R; Hendrickson R; Hu W; Bargonetti J
bioRxiv; 2024 Jan; ():. PubMed ID: 38328189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
